Averin Insights

Averin Capital
  • 0.0 (0)
  • Investing

Averin Insights is the podcast from Averin Capital, an early-stage venture capital firm investing in AI and breakthrough technologies transforming human health. Host David Berry, MD, PhD, co-founder of Averin and former General Partner at Flagship Pioneering, talks with scientists, physicians, founders and executives about drug discovery, AI in hospitals, surgical robotics, longevity, healthcare regulation and building health companies.

Episodes

  1. Oct 26

    Entrepreneurial Impact Amplified with Sangeeta Bhatia

    Can we change the signals we measure to better understand disease? Sangeeta Bhatia joins David Berry to discuss new approaches to cancer detection, synthetic biomarkers and the promise of hepatocytes as liver cell therapies. They also explore lessons from Satellite Bio and the Faculty Founder Initiative’s work helping more women turn academic research into companies. Watch on YouTube: https://youtu.be/zTWQN4gE4pcMore conversations: https://www.averincapital.com/averin-insights 00:00 Introduction 01:07 Early versus wrong 02:20 Rethinking liquid biopsy 07:56 Synthetic biomarkers 13:48 The future of home screening 15:45 Hepatocytes and liver therapies 21:13 The Faculty Founder Initiative 28:14 Models for building companies 30:30 Academia and entrepreneurship 32:26 Women and the founder ecosystem 35:08 Advice for the next generation 38:14 Closing reflections

  2. Oct 13

    Building The AI Powered Hospital with Michael Hasselberg

    Michael Hasselberg, Chief Transformation and Digital Officer at Nebraska Medicine, joins David Berry for a practical conversation about how health systems are building and adopting AI. They discuss administrative automation, data governance, the safeguards needed for clinical applications, and how hospitals decide when to build, buy, or rely on existing platforms. Michael also shares his vision for ambient patient rooms, wireless monitoring, and robotics—and why human connection and cybersecurity remain central to care. Watch on YouTube⁠⁠ Episode page⁠ Averin Capital backs and builds early-stage companies transforming human health through AI and breakthrough technology.⁠ Explore Averin Capital

  3. Sep 28

    Accelerating the Speed of Discovery with Andy Plump

    How do you build an AI-native R&D organization without losing the scientific judgment that makes drug development possible? Andy Plump, President of Research & Development at Takeda, joins David Berry on Averin Insights to discuss how technology is changing drug discovery and development. They explore the role of basic science, the changing global research landscape, and how R&D leaders can combine speed, technology, and clinical understanding to bring new medicines to patients. Watch on YouTube Episode page Averin Capital backs and builds early-stage companies transforming human health through AI and breakthrough technology. Explore Averin Capital

  4. Sep 28

    Betting on Breakthrough Biology with Christian Schubert

    How do strategic investors identify promising science and help turn it into a company? Christian Schubert, Vice President and Global Head of AbbVie Ventures, joins David Berry on Averin Insights to discuss early-stage biotech investing, working with founders, and where AI can make a meaningful difference in drug discovery. The conversation explores how corporate venture capital is evolving, how investors build conviction in emerging biology, and what it takes to move scientific ideas toward new medicines. Watch on YouTube Episode page Averin Capital backs and builds early-stage companies transforming human health through AI and breakthrough technology. Explore Averin Capital

  5. Sep 28

    Before Disease Decides with Thierry Bernard

    What if medicine could act before symptoms appear? Thierry Bernard, CEO of QIAGEN, joins David Berry on Averin Insights to explore how diagnostics could help healthcare move from reacting to disease toward earlier detection and more personalized care. They discuss molecular diagnostics, AI, liquid biopsies, and predictive biology—and the work needed to turn new biological signals into useful information for patients and clinicians. Watch on YouTube Episode page Averin Capital backs and builds early-stage companies transforming human health through AI and breakthrough technology. Explore Averin Capital

  6. Mar 27

    The Surgeon Is Still the System with Rony Abovitz, Josh DeFonzo and Chris Morley

    Averin’s David Berry joins Rony Abovitz, Josh DeFonzo, and Chris Morley to explore how robotics, AI, and augmented reality are expanding surgeons’ capabilities. The discussion covers precision and consistency in care, the role of patient demand in adoption, and the next frontier of intervention at the cellular and tissue level.

  7. 12/18/2025

    The New Liquidity Landscape with John Bishai, Paul Kinsella and Will Herrmann

    Averin’s David Berry joins John Bishai, Paul Kinsella, and Will Herrmann to explore exit strategies for healthcare and biotech companies. The discussion covers M&A trends, the outlook for IPOs in 2026, what buyers and investors look for, and how companies can position themselves for a successful exit.

  8. 09/26/2025

    Navigating Healthcare Regulation with Peter Hutt, David Shulkin and Daniel Troy

    Averin’s David Berry joins Peter Hutt, David Shulkin, and Daniel Troy to explore how regulation, AI, and geopolitics are shaping healthcare and biotech. The discussion covers FDA enforcement trends, the challenges of evaluating AI-enabled products, and shifting global supply chains - and what they mean for innovators.

  9. 05/28/2025

    Activated Intelligence: AI’s Leap from Algorithm to Impact with Andrew Hopkins, Jared Saul and Andrey Dobry

    Averin’s David Berry joins Andrew Hopkins, Jared Saul, and Andrey Dobry to explore how AI is transforming healthcare and biotech. The discussion covers AI-designed molecules, the role of data in scientific discovery, and the rise of autonomous systems reshaping drug development.

  10. 04/08/2025

    The Age of Longevity with Nir Barzilai and Michael Ringel

    David Berry joins longevity experts Nir Barzilai and Michael Ringel to explore the science of healthier, longer lives. The discussion covers lessons from centenarians, emerging therapies targeting aging, the promise of epigenetic reprogramming, and investment opportunities in longevity biotech.

  • 10 Episodes

About

Averin Insights is the podcast from Averin Capital, an early-stage venture capital firm investing in AI and breakthrough technologies transforming human health. Host David Berry, MD, PhD, co-founder of Averin and former General Partner at Flagship Pioneering, talks with scientists, physicians, founders and executives about drug discovery, AI in hospitals, surgical robotics, longevity, healthcare regulation and building health companies.

Information

  • Creator
    Averin Capital
  • Years Active
    2026
  • Episodes
    10
  • Rating
    Clean
  • Copyright
    © Averin Capital
  • Show Website
    Averin Insights